Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
- PMID: 1673495
- DOI: 10.1016/0140-6736(91)91709-4
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
Abstract
In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.
Comment in
-
Bronchodilatory action of cysteinyl-leukotriene receptors.Lancet. 1991 Jun 29;337(8757):1618. doi: 10.1016/0140-6736(91)93324-3. Lancet. 1991. PMID: 1675754 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
